STUDY PROTOCOL

Effect of negative pressure wound therapy after surgical removal of deep-seated high-malignant soft tissue sarcomas of the extremities and trunk wall—study protocol for a randomized controlled trial

Mügın Yilmaz*, Andrea Thorn, Michala Skovlund Sørensen, Claus Lindkær Jensen and Michael Mørk Petersen

Abstract

Background: Sarcomas are a heterogeneous group of rare malignant tumors of mesenchymal origin in the musculo-skeletal system. The main treatment is surgery often supplemented with pre-or postoperative radiotherapy. A retrospective study by Bedi et al. indicated that negative pressure wound therapy (NPWT) reduced the risk of postoperative wound complications in patients treated with preoperative radiation followed by surgical tumor removal of lower extremity soft tissue sarcomas (STS), and the use of NPWT was not associated with an increased risk of local recurrence. Previous studies have shown that NPWT can reduce postoperative complications. STS surgeries are a high-risk procedure concerning wound complications.

Methods: Non-blinded single-center randomized controlled trial comparing NPWT versus conventional wound dressing and postoperative wound complications after surgical removal of deep-seated high-malignant STS of the extremities or trunk wall

Sample-size calculation: 154 STS patients (80% risk of avoiding type II error, 5% risk of type I error, and an 80% wound complication risk)

Block randomization of 8 into:

Group A: Conventional wound dressing
Group B: NPWT (PREVENA PLUS™ Incision Management System)

Inclusion criteria: Surgery for a deep-seated STS of an extremity or the trunk wall

Exclusion criteria: Age < 18 years, plastic surgery, low malignant/borderline STS, chemotherapy, preoperative radiotherapy, allergic/hypersensitive to acrylic adhesives or silver, unwilling/unable to provide informed consent, metastatic disease, and ischemic surgeries

*Correspondence: yilmaz_mujgan@hotmail.com

Department of Orthopedic Surgery, University Hospital of Copenhagen, Rigshospitalet, Inge Lehmanns Vej 6, 2100 Copenhagen, Denmark

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Sarcomas are a heterogeneous group of rare malignant tumors of mesenchymal cell origin in the musculoskeletal system comprising 1% of all adult cancers [1]. The reported incidence of all types of sarcomas is approximately six to eight per 100,000 inhabitants corresponding to 300 cases per year in Denmark (250 Soft Tissue Sarcomas (STS) (100 retroperitoneal/abdominal STS), 50 bone sarcomas) [2, 3]. Sarcomas arise in the body’s connective tissues including bone, muscle, cartilage, fat tissue, blood vessels, and peripheral nerve sheaths and hence arise in all parts of the body, however, most dominant (78%) in the extremities [4].

There exist more than 50 histologic subtypes of STS yielding a broad heterogeneous morphology and biological behavior of all subtypes [4]. The incidence of STS increases in general with age (median age = 65) [4]. High-grade STS mostly metastasize hematogenous to the lungs, which is also the primary cause of sarcoma-specific death, and approximately 10% of patients with STS have metastases at diagnosis [5].

Treatment of STS requires a multidisciplinary highly specialized team, evaluating risks and benefits of all available options and expected outcomes with the aim to minimize the recurrence of disease and preserve function and quality of life. The main treatment principle that has largely been unchanged since the 1980s is surgery supplemented with radiotherapy depending on subtype and stage [6]. The use of negative pressure wound therapy (NPWT) after high-risk orthopedic surgeries such as amputations, treatment of open fractures, and joint replacement surgery are increasing, but the direct cost is much higher compared to the conventional wound dressing. However, previous studies have shown that NPWT can reduce postoperative complications such as wound dehiscence and infection [7–10]. STS surgery that is often combined with pre- or postoperative radiation therapy is a high-risk procedure concerning wound complications and postoperative infections [11–13]. A retrospective study showed that NPWT reduced the risk of wound complications in patients with lower extremity STS treated with preoperative radiation and the use of NPWT was not associated with an increased risk of local recurrence [14].

The purpose of this research project is to improve the surgical treatment of STS treatment based upon a randomized controlled trial (RCT). This study aims to compare standard wound closure with staples and conventional wound dressing (control group) with wound closure with staples and NPWT (interventions group). We want to evaluate the effect of the use of NPWT versus a conventional wound dressing on postoperative wound complications after surgical removal of deep-seated high-malignant STS of the extremities or trunk wall.

Methods/design
Study design
The study design is as follows: non-blinded single-center randomized (1:1) controlled trial, with parallel groups and block randomization of 8 patients in each group comparing NPWT versus conventional wound dressing and postoperative wound complications after surgical removal of deep-seated high-malignant STS of the extremities or trunk wall.

Enrolment
Patients evaluated at a multidisciplinary conference and afterward with a biopsy verified STS will be identified in Sundhedsplattormen (electronic patient records); the only information needed from the patient records prior to informed consent is when they will meet in the outpatient clinic. Patients eligible for inclusion will at their first...
outpatient visit to plan further final surgery be informed about the study written and orally. On the day of their surgery, written informed consent will be obtained if they want to participate in this study. No patient will have below 48 h to answer, complying with the Helsinki declaration [15].

All patients will be informed orally and written by the principal investigator, or colleague information will be given in a separate room allocated for only the patient and if wanted the assessor, so interruption does not occur. All patients will be asked if they want an assessor, and then a new meeting will be arranged, and the information will again be given by the principal investigator in a separate room allocated for the patient and the assessor. The written informed consent gives the principal investigator, sponsor, and sponsor's representatives as well as any control authority direct access to obtain information in the patient’s medical record, etc., including electronic medical record, in order to see information about the subject’s health, which is necessary for carrying out the research project and for control purposes, including self-monitoring and quality control, which they are required to perform.

The participants are covered by the Danish Patient Compensation Association (Fig. 1).

Criteria of inclusion

- Surgery for a deep-seated STS of an extremity or the trunk wall at Rigshospitalet

Criteria of exclusion

- Age < 18 years
- Wound closure not possible without plastic surgery (pedicled or free flaps)
- Low malignant (Trojani grade 1) STS or borderline tumors
- Pre- or postoperative chemotherapy
- Preoperative radiotherapy to the local site
- Allergic or hypersensitive to acrylic adhesives or silver
- Unwilling or unable to provide informed consent
- Inability to comply with planned study procedures
- Patients with metastatic disease
- Patients with ischemic surgery such as bypass or endovascular prosthesis

Fig. 1 CONSORT expected flow diagram
• Patients with ischemic surgery such as bypass or endovascular prosthesis

Drop out criteria

• Did not want to participate

Variables collected

• Age
• Gender
• Lifestyle factors such as alcohol consumption, caffeine intake, smoking habits, BMI, and exercise
• Comorbidities, including medical treatments (including but not limited to hypertension, hypercholesterolemia, diabetes mellitus/HbA1C, dialysis dependence, chronic venous insufficiency, end-stage renal disease, congestive heart failure)
• Radiation regime
• Operation time
• Blood loss at surgery
• Pathology
• Tumor location, size, grade depth
• Postoperative medical treatment
• Images

Randomization

All 160 patients will in the operating room be randomized (randomization with 80 patients in each group) to receive one of the two treatments:

Group A: Standard wound closure with staples and conventional wound dressing

Group B: Standard wound closure with staples and NPWT (PREVENA PLUS™ Incision Management System)

Block randomization with 8 patients in each block stratified for upper extremity/truncal wall or lower extremity STS will be performed using a verified computerized irreversible application—the Research Electronic Data Capture (REDCap). The randomization sequence will be computer-generated. This study is not blinded.

The study takes place at the Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen. Patients will be followed in our outpatient clinic; the surgeries will be performed by specialized orthopedic tumor surgeons. Rigshospitalet is a tertiary multidisciplinary sarcoma center performing highly specialized tumor surgeries.

Follow-up

The patient’s wounds will be followed by a member of the department staff or research group with photo documentation on day 0, day 7, at definitive wound healing (removal of staples), 4 months postoperatively, and in case of major wound complication.

Follow-up from day 7 and further on will be performed in the outpatient regime, at Rigshospitalet, orthopedic department; patients will be convened through e-books (secure platform for digital postboxes), and, if necessary, transport will be provided.

Preoperative, after 4 months, and 1 year quality of life will be evaluated with European Quality of Life - 5 Dimensions (EQ-5D) [17]; furthermore, Musculoskeletal Tumor Society Score (MSTS) [18] and Toronto Extremity Salvage Score (TESS) [19] will be used to evaluate function 4 months and 1 year postoperatively depending on surgery location (Fig. 2).

Patient involvement

There has not been any public or patient involvement when designing this protocol.

Main hypotheses

The use of NPWT will result in a decrease of postoperative wound complications after surgical removal of deep-seated high-malignant STS of the extremities or trunk wall compared to a conventional wound dressing.

Primary study endpoints

A major wound complication defined as in O'Sullivan et al. [11]:

• A secondary surgery under anesthesia for wound repairs such as debridement, operative drainage, and secondary wound closure
• Wound management without secondary surgery; this includes invasive procedure without anesthesia such as aspiration of seroma and readmission for wound care such as intravenous antibiotic or persistent deep packing within 4 months (120 days) after surgery

Secondary study endpoints

Length of hospital stay, readmission to hospital for treatment of a wound complication, time to primary wound healing and removal of staples (ready for radiation therapy), deep infection, postoperative seroma development, MSTS [18], and TESS [19] 4 months and 1 year
postoperatively; furthermore, quality of life will be evaluated with EQ-5D [17] preoperatively, at 4 months and 1 year.

**Statistical analysis**

Fisher’s exact test will be used for categorical variables. Depending on if the data could be considered normally distributed or not, a *t*-test for unpaired data or Mann–Whitney *U* test will be used for continuous variables.

Kaplan-Meier survival analysis will be used for overall survival (with log-rank test for comparison of groups). In case of an assumption of a difference in time to delayed wound healing, competing risk analysis will be used to address differences between the groups with death and amputation as competing factors.

All analyses will be performed in accordance with the intention-to-treat principles.

Two-sided *p*-values below 0.05 will be considered statistically significant.

**Calculation of sample size**

In the study of O’Sullivan et al. [11], a major wound complication within 4 months postoperatively was identified in 16 out of 94 (17%) STS patients treated with surgery and postoperative radiation therapy. There exist no studies evaluating the effect of NPWT on wound complications after surgery for STS combined with postoperative radiation therapy. However, in retrospective studies, it was found that NPWT reduced the risk of wound complications from 47 to 8% (83% reduction) in patients with lower extremity STS treated with preoperative radiation [14] and from 27 to 7% (75% reduction) in patients undergoing hip and knee revision surgery [20].

In a study design with an 80% risk of avoiding type II error, a 5% risk of type I error, and an 80% wound complication risk reduction in a population similar to the study by O’Sullivan et al. [11], we will need to include 154 STS patients (77 in each group) in an RCT.

To make allowance for dropouts (since the follow-up period regarding the primary study endpoint is only 4 months = 120 days; few dropouts are expected) during the study period, we plan to include 160 patients.

**Discussion**

The surgical intervention in both groups is equal and according to current standards; the only difference is the wound dressing.
The randomization is planned as block randomization with 8 in each block; furthermore, a stratification of over extremity/trunk wall and under extremities will be performed; this is due to minimizing the risk of selection bias.

Risks, side effects, and disadvantages
We do not expect that the patients participating in the study will experience any special side effects or complications related directly to the specific use of NPWT or the standard wound closure. The dressing may for some patients give a mild skin irritation of the skin under the enclosed dressing or a slight discomfort with having to wear an occlusive dressing. Any transient skin irritation (i.e., resolves within 24 h following device use and requires no medical intervention) will not be classified as an adverse device effect. Some blistering formations have been reported in relation to total hip and knee replacement surgery but no more than patients with conventional dressing [7].

A retrospective study showed that NPWT reduced the risk of wound complications in patients with lower extremity STS treated with preoperative radiation, and the use of NPWT was not associated with an increased risk of local recurrence [14].

No risk or side effects are reported by the manufacturer when adhering to the user manual. Prevena™ NPWT is used daily at the orthopedic department; it is a CE-classified and FDA-approved medical device, and due to use in the recommended field, approval from the Danish Medicines Agency is not necessary.

Ethical considerations
The study is approved by the Scientific Ethical Committee of the Capital Region of Denmark (H-21013549) and the Danish Data Protection Agency (P-2021-150), and it is registered at clinicaltrials.gov (NCT04960332) before the inclusion of patients. All patients will receive both oral and written information before written informed consent to participate is obtained.

The regulation from data protection regulation and data protection agency will always be followed.

The significant use of the present study is new knowledge concerning the best way to treat a certain group of patients with deep-seated STS of an extremity or the trunk wall. Knowledge from our study will benefit society in general and optimize utilization of resources, in terms of the best treatment for future patients.

In case of serious adverse preliminary results, data will be analyzed, and if one of the treatments is found to cause significant critical problems compared to the other (p < 0.05), the study will be ended. The study is thus designed to minimize unnecessary risks to the patients.

Trial status
Protocol version: 07.05.2021 Version 1.2
Recruitment: started
Anticipated completion of recruitment: December 2024

Abbreviations
NPWT: Negative pressure wound therapy; RCT: Randomized controlled trial; STS: Soft tissue sarcoma; REDCap: Research Electronic Data Capture; EQ-SD: European Quality of Life 5 Dimensions; MSTS: Musculoskeletal Tumor Society Score; TESS: Toronto Extremity Salvage Score.

Acknowledgements
Not applicable.

Authors’ contributions
MY: wrote the protocol in collaboration with AT, study design, data collection, will provide help analyzing the results and writing the paper. AT: wrote the protocol in collaboration with MY, data collection, data analysis and performing the draft for the paper. MS: study design, supervision, will provide help analyzing the results and revision of papers. CL: supervision and revision of papers. MP: study design, supervision, and revision of papers. All authors will approve the final paper prior to the submission, and the ICMJE [21] recommendation will be followed.

Funding
The study is initiated by the coordinating responsible investigator. There has been granted a PhD scholarship from Rigs hospital it eks forsknings- spulje (3 years) for conduction of this study (and 2 other STS-related projects), and the amount given in total is 2,040,000 DKK. The donation will be administered by the fund administration, Rigshospitalet. All participants and the ethical committee will be informed if additional financial support is provided cf. committee law §2 nr.7 and the executive order §7 nr.1.

Andrea Thorn will be paid to carry out project functions, while project participants are involved voluntarily, as part of their daily work, and partly as an unpaid volunteer.

For participation in general, there is given no fee, but compensation for transport to the hospital or ticket for parking will be given. The applicant group has no dependence on commercial companies or organizations, with interest in the results of the present study. Hence, such will not influence the interpretation and analysis of the results.

Availability of data and materials
All data will be kept in REDCap, but datasets used and/or analyzed during this current study will be available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Approval from the Scientific Ethical Committee of the Capital Region of Denmark (H-21013549) and the Danish Data Protection Agency (P-2021-150) has been obtained, and the study is registered at clinicaltrials.gov (NCT04960332) before the inclusion of patients. All patients will receive both oral and written information before written informed consent to participate is obtained. This trial will follow the ethics outlined in the Helsinki declaration [15]. Knowledge from our study will benefit society in general and optimize utilization of resources, in terms of the best treatment for future patients.

In case of serious adverse preliminary results, data will be analyzed, and if one of the treatments is found to cause significant critical problems compared to the other (p < 0.05), the study will be ended. The study is thus designed to minimize unnecessary risks to the patients.
If any modification in the protocol is necessary, supplement approval from the Scientific Ethical Committee and Danish Data Protection Agency is needed to be obtained, and registration on clinicaltrials.gov as well as patients included is needed to be updated. All results, whether positive, negative, and inconclusive from the trial, will be published in leading international peer-reviewed scientific orthopedic journals and also be presented at scientific meetings. Furthermore, all results will also be presented at local meetings.

Consent for publication
All authors give consent for the publication, and the ICMJE Form for Disclosure of Potential Conflicts of Interest [22] will be completed by each author.

Competing interests
The authors declare that they have no competing interests.

Received: 9 August 2021    Accepted: 9 June 2022

Published online: 18 June 2022

References
1. Lahat G, Lazar A, Lev D. Sarcoma epidemiology and etiology: potential environmental and genetic factors. Surg Clin North Am. 2008;88(3):451–81.
2. Jorgensen PH, Lausten GS, Pedersen AB. The Danish Sarcoma Database. Clin Epidemiol. 2016;8:685–90.
3. Ducimetiere F, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294.
4. World Health Organization WHD. In: Fletcher C, Bridge JA, Hogendoorn PCW, editors. WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol. 5. 4th ed. World Health Organization; 2013. p. 468.
5. Yejs L, et al. Surgical innovation in sarcoma surgery. Clin Oncol (R Coll Radiol). 2017;29(8):489–99.
6. Grimmer R, et al. Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010;2010:506182.
7. Redfearn RE, et al. Closed incision negative pressure therapy effects on postoperative infection and surgical site complication after total hip and knee arthroplasty. J Arthroplasty. 2017;32(11):3333–9.
8. Helito CP, et al. The use of negative-pressure wound therapy after total knee arthroplasty is effective for reducing complications and the need for reintervention. BMC Musculoskelet Disord. 2020;21(1):490.
9. Newman JM, et al. Use of closed incisional negative pressure wound therapy after revision total hip and knee arthroplasty in patients at high risk for infection: a prospective, randomized clinical trial. J Arthroplasty. 2019;34(3):554–559 e1.
10. Zayan NE, et al. Incisional negative pressure wound therapy: an effective tool for major limb amputation and amputation revision site closure. Adv Wound Care (New Rochelle). 2019;8(8):368–73.
11. O’Sullivan B, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41.
12. Moore J, et al. Major wound complication risk factors following soft tissue sarcoma resection. Eur J Surg Oncol. 2014;40(12):1671–6.
13. Schwartz A, et al. Risk factors for significant wound complications following wide resection of extremity soft tissue sarcomas. Clin Orthop Relat Res. 2013;471(11):3612–7.
14. Bedi M, et al. Does vacuum-assisted closure reduce the risk of wound complications in patients with lower extremity sarcomas treated with preoperative radiation? Clin Orthop Relat Res. 2019;477(4):768–74.
15. WMA Declaration of Helsinki – ethical principles for medical research involving human subjects [Internet]. July 2018 [Cited June 2021]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/.
16. Guillo L, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62.
17. Herdman M, et al. Development and preliminary testing of the new five-level version of EQ-SD (EQ-SD-5L). Qual Life Res. 2011;20(10):1727–36.
18. Saebye CK, Keller J, Baad-Hansen T. Validation of the Danish version of the musculoskeletal tumour society score questionnaire. World J Orthop. 2019;10(1):23–32.
19. Saebye C, et al. Validation of a Danish version of the Toronto Extremity Salvage Score questionnaire for patients with sarcoma in the extremities. Dan Med J. 2014;61(1):A4734.
20. Cooper HJ, Bas MA. Closed-incision negative-pressure therapy versus antimicrobial dressings after revision hip and knee surgery: a comparative study. J Arthroplasty. 2016;31(5):1047–52.
21. ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals [Internet]. 2018 [cited June 2021]. Available from: http://www.icmje.org/icmje-recommendations.pdf.
22. ICMJE Form for Disclosure of Potential Conflicts of Interest. Feb 2021 (Cited June 2021). Available from: http://www.icmje.org/disclosure-of-interest/.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.